Turkish Journal of Gastroenterology
POSITION STATEMENT

Turkish IBD Organization’s Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic

1.

Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey

2.

Department of Gastroenterology, TOBB University of Economics and Technology School of Medicine, Ankara, Turkey

3.

Department of Gastroenterology, İstanbul University İstanbul School of Medicine, İstanbul, Turkey

4.

Department of Gastroenterology, Trakya University School of Medicine, Edirne, Turkey

5.

Department of Gastroenterology, İstanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, İstanbul, Turkey

Turk J Gastroenterol 2021; 32: 488-492
DOI: 10.5152/tjg.2021.280721
Read: 483 Downloads: 180 Published: 02 August 2021

The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2, has resulted in high mortality and morbidity worldwide and is still a growing problem. Inflammatory bowel disease (IBD) is a chronic inflammatory disease for which a substantial number of patients are treated with immunosuppressive medications, either occasionally or long-term. Despite the accumulating evidence, there is still a lack of knowledge about the impact of COVID-19 on IBD patients, especially those who are under immunosuppressive treatment. Moreover, following the emergence of several COVID vaccines, there are concerns regarding vaccine effectiveness and possible side effects in such patients. In this context, we tried to briefly summarize the accumulating evidence and recommendations for the management of IBD in the context of the COVID-19 pandemic.

Cite this article as: Aydın MF, Taşdemir H. Ulcerative colitis in a COVID-19 patient: A case report. Turk J Gastroenterol. 2021; 32(6): 543-547.

Files
EISSN 2148-5607